Mineralys Therapeutics (MLYS) Q4 2025 earnings review
Transitioning to Commercial Prep as R&D Burn Plummets
Mineralys has officially shifted from a clinical-stage development story to a regulatory waiting game. Financial trends are reversing: R&D expenses nearly halved in Q4 as pivotal trials wrapped up, while G&A almost doubled as commercial build-out accelerates. A massive $656 million cash pile guarantees runway into 2028, eliminating any financing overhang ahead of the December 2026 PDUFA date for lorundrostat. However, the pipeline narrative took a direct hit this quarter: the Phase 2 Explore-OSA trial completely missed its primary endpoint, killing a key catalyst that management heavily promoted in prior quarters.
🐂 Bull Case
With $656.6M in cash and investments (up from $198.2M a year ago), the company is fully funded into 2028. This removes the dilution risk that typically plagues pre-commercial biotechs.
The FDA officially accepted the NDA for lorundrostat in adult hypertension. The December 22, 2026 PDUFA date provides a concrete timeline for potential commercialization.
🐻 Bear Case
The Phase 2 trial in obstructive sleep apnea failed to show a clinically meaningful difference in AHI versus placebo. This wipes out a major intended label expansion.
With G&A climbing 93% YoY and no partnership announced, the company appears to be bearing the full cost of a commercial build-out to reach 47,000 target prescribers.
⚖️ Verdict: ⚪
Neutral. The core hypertension asset is secure and heavily funded, but the failure of the OSA trial strips away upside optionality, and going it alone commercially carries significant execution risk.
Key Themes
NDA Acceptance and Concrete PDUFA Date
Stable. The primary value driver is officially in the FDA's hands. The accepted NDA for lorundrostat sets a PDUFA target date of December 22, 2026. This transitions Mineralys from a speculative clinical entity to an organization executing pre-commercial strategies.
Explore-OSA Trial Fails Primary Endpoint
Reversing. In previous quarters, management heavily promoted the Explore-OSA trial as a key differentiator to target nocturnal aldosterone surges. The Q4 release confirmed lorundrostat failed its primary endpoint (no clinically meaningful difference in Apnea-Hypopnea Index). This specifically contradicts the positive comorbidity expansion narrative built around the drug.
G&A Spend is Accelerating Rapidly
Accelerating. General and Administrative expenses doubled in Q4 to $13.9M (from $7.2M in 24Q4). This highlights the expensive reality of building a commercial infrastructure and expanding headcount long before revenue materializes.
Partnering Radio Silence
Stable. Throughout early 2025 calls, management insisted that partnering (especially ex-US) was a key component of their strategy. The Q4 PR makes absolutely no mention of partnership progress, suggesting they are either struggling to find favorable terms or have pivoted entirely to an independent commercial launch.
Unwavering Blood Pressure Efficacy
Stable. Even in the failed Explore-OSA trial, lorundrostat demonstrated a clinically meaningful blood pressure reduction of 11.1 mmHg at week four (6.2 mmHg placebo-adjusted). This reaffirms the core CYP11B2 inhibition mechanism works consistently across diverse patient populations.
Runway Extends Past Launch
Accelerating. Cash surged to $656.6M. Unlike many biotechs that have to raise money immediately upon FDA approval, Mineralys has secured funding into 2028, ensuring they can absorb initial commercialization cash burn without tapping equity markets from a position of weakness.
Other KPIs
Decelerating. Down 45% YoY from $44.6M in 24Q4. The drop is a direct result of wrapping up the massive Launch-HTN and Advance-HTN pivotal clinical trials in the second quarter of 2025. Expect this to remain relatively stable as long-term extension studies continue.
Decelerating. Improved from a loss of $48.9M a year ago. The reduction in R&D costs massively outweighed the increase in G&A, resulting in a shrinking net loss footprint. Combined with higher interest income on their $656M cash pile, the overall burn rate is highly manageable.
Accelerating. Up from $14.6M in 2024. Thanks to the massive cash influx from two 2025 equity offerings, interest income is now covering more than 40% of the company's annual G&A expenses.
Guidance
Accelerating vs prior year guidance (which was 2026). The massive capital raises in 2025 guarantee that Mineralys will not face a liquidity crunch before, during, or immediately after the PDUFA date.
Stable. This represents the finish line for the regulatory phase and provides a firm anchor for modeling commercialization spend throughout late 2025 and 2026.
Key Questions
Explore-OSA Failure Implications
With the failure to meet the primary AHI endpoint in Explore-OSA, are you abandoning sleep apnea as a target indication entirely, or do you plan to analyze subgroups for a potential pivot?
Commercial Partnership Status
You previously emphasized a desire for commercial partnerships to access the 47,000 target prescribers. Does the accelerated G&A build-out indicate you are preparing to launch independently in the US?
G&A Expense Ramp
G&A expenses nearly doubled in Q4. How should we model the trajectory of this spend through 2026 as we approach the December PDUFA date?
Transform-HTN Update
When do you plan to present the long-term safety and efficacy data from the ongoing Transform-HTN Open-Label Extension Trial?